13F Pro

SEC Form 4 reporting owner

Enright Patrick G

Enright Patrick G has filed 13 Form 4 transactions reported between August 18, 2025 and August 31, 2026, as Director of Jazz Pharmaceuticals plc, Director of Zenas BioPharma, Inc., a reporting owner of BioAge Labs, Inc., a reporting owner of Vera Therapeutics, Inc. and Director of Veradermics, Inc.

Name as filed: ENRIGHT PATRICK G

Open-market buys, 24 mo
$250K
1 lines
Open-market sales, 24 mo
None
reported
Companies
5
with Form 4 filings
Latest transaction
Aug 31, 2026
transaction date

Roles and reported holdings

  • JAZZJazz Pharmaceuticals plc
    Aug 18, 2025 – Aug 31, 2026

    Director

    Held directly21,278 sh as of Aug 31, 2026 · Form 4
  • ZBIOZenas BioPharma, Inc.
    Jun 15, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • BIOABioAge Labs, Inc.
    Jun 10, 2026

    Reporting owner

    No common-stock holding reported on a purchase, sale, gift or withholding line.

  • VERAVera Therapeutics, Inc.
    Dec 11, 2025 – May 21, 2026

    Reporting owner

    Held directly5,882 sh as of Dec 11, 2025 · Form 4

    24 months: $250K bought

  • MANEVeradermics, Inc
    Feb 3, 2026 – Feb 5, 2026

    Director

    No common-stock holding reported on a purchase, sale, gift or withholding line.

    2 lines are priced far from MANE’s market price that day, so the filing may concern a different security. Left out of totals and holdings; see the filings.

Transaction history

All 13 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Aug 31, 2026JAZZDirectorShares withheld for tax or exercise priceCode F · direct1,692$408K@ $241.39Form 4
Aug 31, 2026JAZZDirectorShares withheld for tax or exercise priceCode F · direct14$3K@ $244.64Form 4
Aug 5, 2026JAZZDirectorGrant or awardCode A · direct1,605—Form 4
Jun 15, 2026ZBIODirectorGrant or awardCode A · direct18,500—Form 4
Jun 10, 2026BIOAGrant or awardCode A · direct22,000—Form 4
May 21, 2026VERAGrant or awardCode A · direct17,084—Form 4
Feb 5, 2026MANEDirectorOpen-market purchaseCode P · indirectPrice far from market; may be another securityAlso reported by Longitude Capital Partners V, LLC882,353$15.0M@ $17.00Form 4
Feb 5, 2026MANEDirectorOpen-market purchaseCode P · indirectPrice far from market; may be another securityAlso reported by Longitude Capital Partners V, LLC192,647$3.3M@ $17.00Form 4
Feb 5, 2026MANEDirectorConversion of derivativeCode C · indirect1,171,121—Form 4
Feb 5, 2026MANEDirectorConversion of derivativeCode C · indirect1,236,631—Form 4
Feb 3, 2026MANEDirectorGrant or awardCode A · direct45,131—Form 4
Dec 11, 2025VERAOpen-market purchaseCode P · direct5,882$250K@ $42.50Form 4
Aug 18, 2025JAZZDirectorOther acquisition or dispositionCode J · direct5,000—Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

2 open-market lines are priced outside 0.67×–1.5× of the stock’s closing price that day. A gap that large usually means the filing reports a different security than the company it is filed under, so those lines are shown but left out of totals and holdings.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.